In the context of systemic lupus erythematosus (SLE), the administration of corresponding metabolic inhibitors, as metformin for OXPHOS and 2-Deoxy-D-glucose (2-DG) for glycolysis, reduce cytokine production of CD4+ T cells and ameliorate kidney damage (Table 1) (105). The gene discussed is CD4; the disease is systemic lupus erythematosus.